当前位置:
X-MOL 学术
›
J. Diabetes Investig.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
New perspective on type 2 diabetes, dyslipidemia and non-alcoholic fatty liver disease.
Journal of Diabetes Investigation ( IF 3.1 ) Pub Date : 2020-05-12 , DOI: 10.1111/jdi.13258 Takashi Matsuzaka 1 , Hitoshi Shimano 1
Journal of Diabetes Investigation ( IF 3.1 ) Pub Date : 2020-05-12 , DOI: 10.1111/jdi.13258 Takashi Matsuzaka 1 , Hitoshi Shimano 1
Affiliation
Serum lipid abnormalities (dyslipidemias) are major risk factors for cardiovascular disease in type 2 diabetes mellitus. Recent findings provide new evidence that dyslipidemia characterized by elevated triglycerides and non‐high‐density lipoprotein cholesterol levels with a decreased high‐density lipoprotein cholesterol level are risk factors for cardiovascular disease in patients with type 2 diabetes. There are multiple therapeutic agents to help patients to achieve target lipid levels, but understanding the molecular mechanisms could provide useful information for new treatment strategies for diabetic dyslipidemia.
中文翻译:
2型糖尿病,血脂异常和非酒精性脂肪肝疾病的新观点。
血清脂质异常(血脂异常)是2型糖尿病心血管疾病的主要危险因素。最新发现提供了新的证据,以甘油三酸酯升高和非高密度脂蛋白胆固醇水平升高,高密度脂蛋白胆固醇水平降低为特征的血脂异常是2型糖尿病患者心血管疾病的危险因素。有多种治疗剂可帮助患者达到目标血脂水平,但了解分子机制可为糖尿病血脂异常的新治疗策略提供有用的信息。
更新日期:2020-05-12
中文翻译:
2型糖尿病,血脂异常和非酒精性脂肪肝疾病的新观点。
血清脂质异常(血脂异常)是2型糖尿病心血管疾病的主要危险因素。最新发现提供了新的证据,以甘油三酸酯升高和非高密度脂蛋白胆固醇水平升高,高密度脂蛋白胆固醇水平降低为特征的血脂异常是2型糖尿病患者心血管疾病的危险因素。有多种治疗剂可帮助患者达到目标血脂水平,但了解分子机制可为糖尿病血脂异常的新治疗策略提供有用的信息。